
Cancer Care Decision Dilemma: The Value Exploration of Onconomics Plus Integrated Analysis
In the process of cancer care, formulating a precise and personalized care plan has always been a major challenge. Traditional imaging and tumor marker tests are commonly used but often fail to comprehensively reflect the real-time dynamics and microscopic biological characteristics of tumors. With rapid advancements in liquid biopsy and genetic testing technologies, RGCC’s Onconomics Plus integrated analysis provides richer and more accurate data to support personalized care decisions, enabling healthcare teams to adjust care plans in a timely manner and ultimately improve patient prognosis and quality of life.








